MarketCapExport financials
Revolution Medicines (RVMD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Revolution Medicines Balance Sheet 2025-2011 | RVMD
Brief overview of Revolution Medicines's financial position
This overview follows the five latest available annual observations between 2021 and 2025.
The asset base grew from $738 million to $2.4 billion, or +219%. Average annual growth of roughly 33.6% was strong.
Liability growth of +434.1% exceeded asset growth of +219%, increasing reliance on outside funding.
The equity ratio reached 69.3% from 81.7%. A high capital share reduces dependence on liabilities.
Net debt moved below zero to -$225 million, reflecting surplus cash over debt.
Cash equals 16.3% of the balance sheet, compared with 14.7% five periods ago. This is the readily available cushion.
Retained earnings remain negative at -$2.9 billion. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Conclusion
Revolution Medicines's balance sheet is broadly resilient, though selected areas require monitoring. The balance between assets, equity and liabilities remains the key issue.
Annual Balance Sheet Revolution Medicines
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-225 M | -407 M | -608 M | -97.2 M | -41.9 M | - | -16.5 M | -69.4 M | -9.08 M | - | - | - | - | - | - |
Long Term Debt |
142 M | 123 M | 80.6 M | 57.4 M | 60.4 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
16.5 M | 12.9 M | 7.37 M | 6.77 M | 6.21 M | 3.67 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 24.9 M | 43.4 M | 2.95 M | - | - | - | - | - | - |
Total Current Liabilities |
290 M | 164 M | 144 M | 62 M | 60.4 M | 47.2 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
723 M | 293 M | 236 M | 127 M | 135 M | 92.7 M | 68 M | 73.9 M | 10.5 M | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | 4.46 M | 12.4 M | 12.1 M | 17.1 M | 16.8 M | - | - | - | - | - | - | - |
Retained Earnings |
-2.87 B | -1.74 B | -1.14 B | -701 M | -453 M | -266 M | -157 M | -110 M | -67.9 M | - | - | - | - | - | - |
Total Assets |
2.35 B | 2.56 B | 2.06 B | 812 M | 738 M | 567 M | 221 M | 171 M | 15.1 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
384 M | 543 M | 696 M | 161 M | 108 M | 104 M | 16.7 M | - | - | - | - | - | - | - | - |
Book Value |
1.63 B | 2.27 B | 1.83 B | 685 M | 603 M | 475 M | 153 M | 96.7 M | 4.53 M | - | - | - | - | - | - |
Total Shareholders Equity |
1.63 B | 2.27 B | 1.83 B | 685 M | 603 M | 475 M | -153 M | -108 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Revolution Medicines
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
138 M | 140 M | 142 M | 120 M | 121 M | 123 M | 78.3 M | 79.1 M | 79.9 M | 80.6 M | 57.1 M | 57.5 M | 57.7 M | 57.4 M | 58.2 M | 58.9 M | 59.6 M | 60.4 M | 26.8 M | 27.6 M | 28.3 M | 29 M | 29 M | 29 M | 29 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.72 B | 754 M | 655 M | 564 M | 287 M | 293 M | 197 M | 190 M | 183 M | 236 M | 147 M | 143 M | 121 M | 127 M | 144 M | 134 M | 132 M | 135 M | 96.8 M | 89 M | 89.1 M | 92.7 M | 92.7 M | 92.7 M | 92.7 M | 68 M | 68 M | 68 M | 68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | 1.43 M | 4.46 M | 9.69 M | 9.69 M | 11.4 M | 12.4 M | 12.7 M | 8.34 M | 9.96 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-3.97 B | -3.32 B | -2.5 B | -2.2 B | -1.95 B | -1.74 B | -1.54 B | -1.39 B | -1.25 B | -1.14 B | -976 M | -868 M | -769 M | -701 M | -645 M | -572 M | -510 M | -453 M | -400 M | -347 M | -303 M | -266 M | -266 M | -266 M | -266 M | -157 M | -157 M | -157 M | -157 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
4.32 B | 2.25 B | 2.25 B | 2.43 B | 2.37 B | 2.56 B | 1.76 B | 1.81 B | 1.91 B | 2.06 B | 984 M | 1.07 B | 1.07 B | 812 M | 826 M | 633 M | 683 M | 738 M | 735 M | 774 M | 812 M | 567 M | 567 M | 567 M | 567 M | 221 M | 221 M | 221 M | 221 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
815 M | 441 M | 217 M | 402 M | 334 M | 543 M | 201 M | 276 M | 288 M | 696 M | 358 M | 380 M | 427 M | 161 M | 179 M | 106 M | 97.7 M | 108 M | 129 M | 196 M | 352 M | 104 M | 104 M | 104 M | 104 M | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 69.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
2.61 B | 1.5 B | 1.6 B | 1.87 B | 2.08 B | 2.27 B | 1.57 B | 1.62 B | 1.73 B | 1.83 B | 837 M | 931 M | 952 M | 685 M | 681 M | 499 M | 551 M | 603 M | 638 M | 685 M | 723 M | 475 M | 475 M | 475 M | 475 M | 153 M | 153 M | 153 M | 153 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
2.61 B | 1.5 B | 1.6 B | 1.87 B | 2.08 B | 2.27 B | 1.57 B | 1.62 B | 1.73 B | 1.83 B | 837 M | 931 M | 952 M | 685 M | 681 M | 499 M | 551 M | 603 M | 638 M | 685 M | 723 M | 475 M | 475 M | 475 M | 475 M | -153 M | -153 M | -153 M | -153 M | -108 M | - | - | - | -67.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Revolution Medicines, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
China
Britain
Australia
Israel
Germany
Canada
Russia
